Literature DB >> 17452675

Lessons learned in the management of advanced pancreatic cancer.

Eric Van Cutsem, Chris Verslype, Patrick A Grusenmeyer.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17452675     DOI： 10.1200/JCO.2006.09.4664

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.

Authors:  Neha Kabra Woods; Jaya Padmanabhan
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

Review 2.  A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.

Authors:  Giannis Mountzios; Kostas N Syrigos
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

Review 3.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

4.  The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Authors:  Meredith A Morgan; Leslie A Parsels; Laura E Kollar; Daniel P Normolle; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.

Authors:  Koh Furugaki; Toshiki Iwai; Kumiko Kondoh; Yoichiro Moriya; Kazushige Mori
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

6.  Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway.

Authors:  Zhonglu Peng; Zhengyu Ji; Fang Mei; Meiling Lu; Yu Ou; Xiaodong Cheng
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 7.  Current immunotherapeutic approaches in pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Shintaro Tsukinaga; Jimi Mitobe; Shunichi Odahara; Toyokazu Yukawa; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Masaki Ito; Hideo Komita; Hiroshi Arakawa; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2011-09-14

8.  Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Authors:  R Hill; M Rabb; P A Madureira; D Clements; S A Gujar; D M Waisman; C A Giacomantonio; P W K Lee
Journal:  Cell Death Dis       Date:  2013-09-05       Impact factor: 8.469

Review 9.  Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.

Authors:  Toshinori Ozaki; Meng Yu; Danjing Yin; Dan Sun; Yuyan Zhu; Youquan Bu; Meixiang Sang
Journal:  BMC Cancer       Date:  2018-03-20       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.